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CLINICAL STUDY
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Abstract
We aimed to evaluate the cancer detection rates of 6-, 10-, 12-core biopsy regimens and the
optimal biopsy protocol for prostate cancer diagnosis in patients with renal failure. A total of
122 consecutive patients with renal failure underwent biopsy with age-specific prostate-specific
antigen (PSA) levels up to 20 ng/mL. The 12-core biopsy technique (sextant biopsy + lateral
base, lateral mid-zone, lateral apex, bilaterally) performed to all patients. Pathology results
were examined separately for each sextant, 10-core that exclude parasagittal mid-zones from
12-cores (10a), 10-core that exclude apex zones from 12-cores (10b) and 12-core biopsy
regimens. Of 122 patients, 37 (30.3%) were positive for prostate cancer. The cancer detection
rates for sextant, 10a, 10b and 12 cores were 17.2%, 29%, 23.7% and 30.7%, respectively. Biopsy
techniques of 10a, 10b and 12 cores increased the cancer detection rates by 40%, 27.5% and
43.2% among the sextant technique, respectively. Biopsy techniques of 10a and 12 cores
increased the cancer detection rates by 17.1% and 21.6% among 10b biopsy technique,
respectively. There were no statistical differences between 12 core and 10a core about cancer
detection rate. Adding lateral cores to sextant biopsy improves the cancer detection rates.
In our study, 12-core biopsy technique increases the cancer detection rate by 5.4% among 10a
core but that was not statistically different. On the other hand, 12-core biopsy technique
includes all biopsy regimens. We therefore suggest 12-core biopsy or minimum 10-core
strategy incorporating six peripheral biopsies with elevated age- specific PSA levels up to
20 ng/mL in patients with renal failure.
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Introduction
The wide spread use of prostate-specific antigen (PSA) and
transrectal ultrasound (TRUS)-guided needle biopsy dramat-
ically improved the detection rate of early prostate cancer.
Since Hodge et al. first introduced TRUS-guided sextant
prostate biopsy, it has been the most widely used method
for diagnosing prostate cancer.1 Sextant biopsy false negative
cancer detection rates ranged from 20 to 35% according to the
clinical characteristics of studied population.2,3 After discov-
ery of prostate cancer stems from the most common prostate
peripheral zone, the importance of the need for a very good
sampling of the peripheral zone started to be questioned
during the diagnosis. Eskew et al. reported that cancer
detection rate would increase up to 35% with 13-core biopsy
strategy.4 In 1999, Chen et al. reported that, the highest cancer
detection rate was achieved with the 11-core biopsy strategy,
based on computer simulations of radical prostatectomy
specimens.4,5 Ellabady et al. reported extended 12-core
prostate biopsy significantly increases both the detection
rate of prostate cancer and the accuracy of biopsy Gleason
score.6
There have been improvements in survival rates of patients
with renal failure.7 As the survival time of patients with renal
failure has increased, the number of elderly patients with renal
failure has also increased.7 Thus, the potential for develop-
ment of prostate cancer has become a real concern, given
the increase in elderly patients with renal failure.8 This study
was conducted to evaluate the diagnostic yield of TRUS-
guided 6-, 10-, 12-core prostate biopsy regimens in patients
with renal failure.
Materials and methods
Between December 2004 and October 2013, 122 consecutive
men with renal failure and suspected prostate cancer were
included in the study. Renal failure or chronic kidney
disease (CKD) was defined as glomerular filtration rate
(GFR) less than 60 mL/min per 1.73 m2 according to CKD
stage 3 (moderate decrease of GFR: 30–59 mL/min per
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1.73 m2).9 Indications for TRUS-guided prostate biopsy were:
abnormal digital rectal examination and/or a serum PSA over
2.5 ng/mL and less than 20 ng/mL. None of these patients had
previous prostate biopsies. All patients were thoroughly
examined by TRUS before biopsy and prostate volumes
were calculated using an ellipsoid prostate formula. All of the
lesions detected by TRUS were noted. Local anesthesia of 5
cc lidocaine (1%) was applied to prostate apex and base. All
of the patients were placed in the left lateral decubitus
position and all were examined with no bowel preparation.
We used an 18 G core biopsy needle mounted on a spring-
loaded automatic biopsy gun. The 12-core biopsy technique
(sextant biopsy + lateral base, lateral mid-zone, lateral apex,
bilaterally) performed to all patients. Besides the sextant
technique, six more biopsies were obtained from the lateral
peripheral zones of base, mid-zone and apex of the prostate,
as depicted in Figure 1. Pathology results were examined
separately for each sextant described by Hodge et al.,1 10 core
that exclude parasagittal mid zones from 12 cores (10a)
described by Gore et al. (Figure 1),10 10 core that exclude
apex zones from 12 cores (10b) described by Presti et al.
(Figure 1)11 and 12-core biopsy regimens. All patients
underwent the same biopsy protocol regardless of the prostate
gland size. Pathology results were examined separately for
each sextant, 10 core that exclude parasagittal mid zones from
12 cores (10a), 10 core that exclude apex zones from 12 cores
(10b) and 12-core biopsy regimens. All of the patients
tolerated the biopsy procedure well and none of the patients
needed intravenous sedation or narcotic analgesics. Informed
consent was obtained from each patient. The Institutional
Review Board approved the clinical protocol.
SPSS for Windows 11.0’ (Chicago, IL) was used for
statistical analysis of the data. Chi-square test was used for
statistical analysis and p50.05 was considered statistically
significant.
Results
Median patients age was 62 (range 42–93). Median pre-
biopsy PSA was 8.4 ng/mL (range 2.4–20) and median
prostate volume was 51 cc (range 13–139). The mean disease
duration of renal failure was 3.58 years. Thirty-seven (30.3%)
of 122 patients had prostate adenocarcinoma at biopsy.
The mean age, mean PSA value and mean prostate volume of
the patients with prostate cancer was 66.7 years, 10.2 ng/mL,
43.48 cc, respectively. On the other hand, the mean age, mean
PSA value and mean prostate volume of the patients with no
prostate cancer at biopsy was 63 years, 7.7 ng/mL, 54.46 cc,
respectively. The overall patients’ age and PSA value
were significantly higher in prostate adenocarcinoma group.
The overall prostate volume was significantly higher in
benign prostatic hyperplasia (BPH) group (Table 1).
Of the 37 cancers diagnosed, total 137 cores were positive
and of these positive cores 61 (44%) was on the standard
sextant biopsy location and 76 (56%) was on lateral biopsy
location (p50.005). On the focal analysis the most common
cancer localizations were bilateral apex lateral cores (total
23.07%). Pathological reports of all 122 patients were
analyzed separately each for sextant, 10a, 10b and 12 cores
and cancer detection rates of each protocol was 17.2%
(21/122), 29% (35/122), 23.7% (29/122) and 30.7% (37/122),
respectively (Table 2).
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Figure 1. Location of prostate biopsy schemes. A: Right base lateral,
B: Right middle lateral, C: Right apex lateral, D: Left base lateral,
E: Left middle lateral, F: Left Apex lateral, G: Right base middle,
H: Right middle middle, I: Right apex middle, J: Left base middle,
K: Left middle middle, L: Left apex middle.
Table 1. Demographic data of patients.
Prostate
adenocancer
Benign
prostatic
hyperplasia Total p Value
Number of patients (%) 37 (30.3) 85 (69.7) 122
Age (years) 48–93 42–86 42–93 50.005
Median 66.7 63 62
PSA (ng/mL) 3.3–18.8 2.4–20 2.4–20 50.005
Median 10.2 7.7 8.4
Prostate volume (cc) 13–127 15–139 13–139 50.005
Median 43.48 55.46 51.08
Table 2. Biopsy technique and cancer detection rates.
Biopsy technique Cancer detection rate (%)
Sextant biopsy 17.2 (21/122)
10a-core biopsy 29.0 (35/122)
10b-core biopsy 23.7 (29/122)
12-core biopsy 30.7 (37/122)
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Sextant biopsy technique compared with 10a-, 10b- and
12-core techniques and we found 10a-, 10b- and 12-core
biopsy techniques increased cancer detection rates according
to sextant biopsy 40% (14/35), 27.5% (8/29) and 43.2%
(16/37), respectively (p50.005). When we compare 10b
biopsy technique with 10a- and 12-core biopsy techniques,
we found 10a- and 12-core biopsy techniques increased
cancer detection rates according to 10b biopsy technique
17.1% (6/35) and 21.6% (8/37), respectively (p50.005).
Only 2 (5.4%) patients dismissed with 10a biopsy tech-
nique according to 12-core biopsy techniques and when we
compared 10a biopsy technique and 12-core biopsy tech-
niques there were no statistically differences between cancer
detection rates (p40.005; Table 3).
Discussion
Studies previously have reported a higher incidence of
malignant diseases in patients with renal failure than in the
general population, and this tendency is marked among
patients with prostate cancer.12–15 This higher incidence
could be explained by several reasons as follows: presence of
chronic infection particularly in the urinary tract, weakened
immune system, nutritional deficiencies and altered DNA
repair.16 Furthermore, the age of patients with renal failure
has increased with progression in the field of therapy,
suggesting a proportional increase in the prevalence of
prostate cancer among these patients.17 Recently, it is also
reported that in patients with renal failure age-stratified PSA
was higher than in the general population. And the cancer
detection rate was increased in patients with renal failure
compared to that in patients with normal renal function at
specific PSA intervals.15 The authors concluded that lower
PSA cutoffs may be appropriate to recommend prostate
biopsy in patients with end-stage renal disease.15
Another study investigating the association of CKD and
cancer risk in older people reported that the risk for lung and
urinary tract cancers but not prostate was higher among men
with CKD.18 The results of that study show no site-specific
increased risk for prostate cancer in men. Prostate cancer
incidence rate was 4.71% in patients with a GFR of560 mL/
min per 1.73 m2 and 4.75% in patients with a GFR of
60 mL/min per 1.73 m2. Reduced kidney function to the
lowest threshold of GFR (540 mL/min) was significantly
associated with lung and urinary tract cancers in men but
showed no significant association for colorectal, breast,
and prostate cancers after adjustment for the effect of age,
smoking status, sun-related skin damage, and diastolic blood
pressure.18
TRUS-guided systematic prostate biopsy remains the gold
standard test for diagnosing prostate cancer. Since Hodge
et al. first introduced (TRUS)-guided sextant prostate biopsy,
it has been the most widely used method for diagnosing
prostate cancer but numerous studies have demonstrated that
increasing the number of cores sampled during prostatic
biopsy will increase the detection rate for prostate cancer.
Authors suggest that sextant biopsy regimen is not sufficient
about number and localization of cores and they report
20–35% of false-negative results.6,19,20 In a systematic review,
Eichler et al. analyzed 87 studies with a total of 20,698
patients and they pooled data from 68 studies. They reported
that increasing number of biopsy cores were significantly
associated with the cancer yield. Schemes with 12 cores
that took additional laterally directed cores detected 31%
more cancers than the sextant scheme and taking more
than 12 cores added no significant benefit.21 In our study,
false-negative result for sextant biopsy was 44% and 16
patients have to be dismissed if only the sextant biopsy was
performed. In 1995, Stamey suggested shifting the sextant
biopsies more laterally in order to sample better the peripheral
zone where most of the cancers are located.22 Chen et al.
compared the ability of different biopsy schemes to detect
cancer and predict tumor volume using prostate biopsy
simulation system in 180 radical prostatectomy specimens.
A total of 1,180,800 individual biopsy tracks were simulated
and they suggest that the detection rate of prostate biopsies
is not related solely to the number of cores taken, core
placement is also important.5 In our study 56% of prostate
cancer located on laterally biopsy cores of 76 cancer focus.
We also observed the most common diagnosed cancer foci
was bilaterally apex laterals (total 23%). Presti et al. added
lateral biopsies of the peripheral zone at the base and mid-
gland to the routine sextant biopsy regimen for a total of
10 systematic biopsies and they found traditional sextant
biopsies missed 20%.11 In our study, we found that this
procedure increased the cancer detection rate 27.5% among
sextant biopsy but missed 21.6% cancer via 12-core biopsy
protocol. Gore et al. in 2001 compared the sensitivity of
different combinations of biopsy cores with those of standard
sextant biopsies and with a 12-core biopsy protocol that
combined the standard sextant biopsy with a complete set of
laterally directed cores. They found combinations of biopsy
cores a strategy that included laterally directed cores at the
base, mid-gland and apex of the prostate with mid lobar and
apical base cores detected 98.5% of cancers and detection rate
of this 10-core biopsy regimen was significantly better than
that of the standard sextant protocol, and was equivalent
to that of the 12-core regional biopsy.10 In our study,
Table 3. Comparison of biopsy techniques.
Cancer detection rates/total
Sextant 10a core 10b core 12 core Increase in cancer detection/total (%) p Value
PSA 2.4–20 ng/mL 21/122 29/122 8/29 27.5 p50.005
21/122 35/122 14/35 40 p50.005
21/122 37/122 16/37 43.2 p50.005
35/122 29/122 6/35 17.1 p50.005
35/122 37/122 2/37 5.4 p40.005
29/122 37/122 8/37 21.6 p50.005
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Gore protocol (10a) was increased the cancer detection rate
among sextant biopsy and Presti (10b) model were 40% and
17.1%, respectively, and cancer detection rate was 94.6%
compared with 12-core biopsy. Gore technique includes
bilaterally lateral apex cores and these regions were the
most cancer detected focus in our study.
The purpose of prostate biopsies was to detect prostate
cancer with minimum inconvenience of the patient whether
with optimal biopsy cores and localizations. In our study,
12-core biopsy protocol in patients with renal failure
increases the cancer detection rate 5.4% among Gore (10a)
biopsy protocol but that was not statistically significant.
On the other hand, 12-core biopsy technique include other
biopsy techniques and provide the all lateral cores sampling;
thus, we suggest 12-core biopsy or minimum 10-core strategy
incorporating at least six peripheral biopsies with age-specific
PSA value 20 ng/mL in patients with renal failure.
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